Post-artesunate Delayed Hemolysis in Patients With Severe Malaria in the United States—April 2019 Through July 2021
Clinical Infectious Diseases · 08.02.2023 · 76 (3) · e857-e863
DOI: 10.1093/cid/ciac719 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 02.09.2022. Verfasst von Francisca Abanyie und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Parasitic Diseases and Malaria, Malaria Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Antimalarials, Artemisinins, Malaria, Malaria, Falciparum. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Background
Studies have demonstrated the safety and efficacy of intravenous artesunate (IVAS) for treatment of severe malaria in endemic and nonendemic countries. However, post-artesunate delayed hemolysis (PADH) is an increasingly recognized phenomenon after its administration. This study describes the prevalence and outcomes of PADH events among severe malaria cases treated with IVAS in the United States.
Methods
Patients diagnosed with severe malaria and treated with IVAS from April 2019 to July 2021 were included. Demographic, clinical, laboratory, therapeutic, and outcome measures were described using proportions, medians, and interquartile range. Patients reported to experience PADH were compared with those not reported to have PADH, and tests of significance were performed.
Results
Of 332 patients included in our analysis, 9 (2.7%) experienced PADH. The majority of infections in both groups were in non-Hispanic Black individuals. Parasite density (11.0% vs 8.0%), admission hemoglobin (11.0 g/dL vs 11.8 g/dL) were similar in the 2 groups. Total bilirubin levels at admission (4.7 mg/dL vs 2.2 mg/dL) and within 8 hours after completion of IVAS (2.6 mg/dL vs 1.2 mg/dL) were notably higher in PADH patients. Cumulative IVAS dose of >9.5 mg/kg and >3 doses of IVAS were risk factors for PADH. The majority (7 of 9) of PADH cases were diagnosed within 2 weeks after initiation of IVAS. Five patients (56%) required blood transfusions, and all recovered without sequelae.
Conclusions
PADH is an uncommon and self-limiting adverse event in many cases; weekly monitoring of hemoglobin and hemolytic markers may identify cases requiring intervention in a timely manner.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Parasitic Diseases and Malaria, Malaria Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
- College of Pharmacy, University of Kentucky, Lexington, Kentucky, USA.
ORCID-Profile: Francisca Abanyie
Zitieren
APA
Abanyie, F., Ng, J., & Tan, K. R. (2023). Post-artesunate Delayed Hemolysis in Patients With Severe Malaria in the United States—April 2019 Through July 2021. Clinical Infectious Diseases, 76(3), e857-e863. https://doi.org/10.1093/cid/ciac719
Vancouver
Abanyie F, Ng J, Tan KR. Post-artesunate Delayed Hemolysis in Patients With Severe Malaria in the United States—April 2019 Through July 2021. Clinical Infectious Diseases. 2023;76(3):e857-e863. doi:10.1093/cid/ciac719
BibTeX
@article{Abanyie2023,
author = {Abanyie, Francisca and Ng, Joanna and Tan, Kathrine R},
title = {Post-artesunate Delayed Hemolysis in Patients With Severe Malaria in the United States—April 2019 Through July 2021},
journal = {Clinical Infectious Diseases},
year = {2023},
volume = {76},
number = {3},
pages = {e857--e863},
doi = {10.1093/cid/ciac719}
}
EUVIMED